Related Experiment Videos
Expression and function of the complement membrane attack complex inhibitor protectin (CD59) on human breast cancer
1Department of Bacteriology and Immunology, University of Helsinki, Finland.
Summary
Human breast cancer cells express protectin (CD59) to resist complement lysis. Blocking this protectin enhances cancer cell susceptibility to complement-mediated killing, offering a potential immunotherapy target.
Area of Science:
- Immunology
- Oncology
- Cell Biology
Background:
- Normal cells use complement inhibitors like protectin (CD59) to prevent lysis.
- Understanding complement inhibitors on cancer cells is vital for immunotherapy.
- Protectin (CD59) is a potent inhibitor of complement-mediated cell lysis.
Purpose of the Study:
- To investigate the expression and function of protectin (CD59) on human breast cancer cells.
- To determine if protectin (CD59) contributes to breast cancer cell resistance to complement.
- To explore the therapeutic potential of targeting protectin (CD59) in breast cancer.
Main Methods:
- Immunofluorescence microscopy to detect protectin (CD59) on tumor samples.
- Immunoaffinity chromatography to isolate and purify protectin (CD59).
- Chromium release assays to assess complement-mediated cytotoxicity and the effect of antibody neutralization.
Main Results:
- Protectin (CD59) was highly expressed on all examined human breast cancer tumors.
- Purified protectin (CD59) inhibited complement lysis when incorporated into cell membranes.
- Neutralizing protectin (CD59) significantly increased breast cancer cell sensitivity to complement-mediated killing.
Conclusions:
- Human breast cancer cells utilize protectin (CD59) to evade complement attack.
- Blocking protectin (CD59) on tumor cells enhances their susceptibility to complement-mediated lysis.
- Targeting protectin (CD59) represents a promising strategy for breast cancer immunotherapy.